Litcius/Paper detail

Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial

Dan-Yun Ruan, Furong Liu, Xiao-Li Wei, Su-Xia Luo, Zhixiang Zhuang, Zhen-Ning Wang, Funan Liu, Yanqiao Zhang, Jianwei Yang, Zhendong Chen, Yongsheng Wang, Junye Wang, Xiaohua Liang, Xiaojie Wu, Yulong Zheng, Jian Li, Xi Shi, Rakesh Kumar, Wei Liu, Chen Bo, Dong‐Sheng Zhang, Rui-Hua Xu

2025The Lancet Oncology57 citationsDOI

Topics & Concepts

MedicineAdverse effectInternal medicineRegimenCancerGastroenterologyResponse Evaluation Criteria in Solid TumorsPhases of clinical researchOncologyClinical trialSurgeryBarrier Structure and Function StudiesHER2/EGFR in Cancer ResearchCell Adhesion Molecules Research
Claudin 18.2-targeting antibody–drug conjugate CMG901 in patients with advanced gastric or gastro-oesophageal junction cancer (KYM901): a multicentre, open-label, single-arm, phase 1 trial | Litcius